Idiopathic pulmonary

Asbestosis Idiopathic Fibrosis Pulmonary Edema Sarcoidosis... 

Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ (2003) Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 100 7947-7952 Agostini C, Gurrieri C (2006) Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3 357-363... 

Cantin, A.M., North, S.L., Fells, G.A., Hubbard, R.C. and Crystal, R.G. (1987). Oxidant mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest. 79, 1665-1675. 

IP4 Inositol tetrakisphosphate IPF Idiopathic pulmonary fibrosis IPO Intestinal peroxidase IpOCOCq Isopropylidene OCOCq I/R Ischaemia-reperfusion IRAP IL-1 receptor antagonist protein IRF-1 Interferon regulatory factor 1 la Short-circuit current ISCOM Immune-stimulating complexes... 

Mitral stenosis or regurgitation Mitral valve prolapse Chronic obstructive pulmonary disease Pulmonary embolism Idiopathic ("lone" atrial fibrillation) Thoracic surgery ... 

Findings from studies of schistosomiasis-induced liver fibrosis, as well as other models of pulmonary, kidney, and liver fibrosis, strongly support the role of CD4+ Th2 cells in the progression of fibrosis (4). In this regard, analyses of gene and protein expression after stimulation by Thl (vs. Th2) cytokines indicates that IL-4 is found at increased concentrations in the bronchoalveolar lavage (BAL) fluid of patients with idiopathic pulmonary fibrosis, as well as in the peripheral blood mononuclear cells of those afflicted with periportal fibrosis (10,53-56). 

Gauldie J. Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002 165(9) 1205-1206. 

Harari S, Caminati A. Idiopathic pulmonary fibrosis. Allergy 2005 60(4) 421 435. 

Abdelaziz MM, Samman YS, Wali SO, Hamad MM. Treatment of idiopathic pulmonary fibrosis is there anything new Respirology 2005 10(3) 284-289. 

Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 2005 11(30) 3943-3971. 

Iyonaga K, Takeya M, Saita N, et al. Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseases. Hum Pathol 1994 25(5) 455-463. 

Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol... 

Capelli A, Di Stefano A, Gnemmi I, Donner CF. CCR5 expression and CC che-mokine levels in idiopathic pulmonary fibrosis. Eur Respir J 2005 25(4) 701-707. 

Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP, 3rd. Idiopathic pulmonary fibrosis pathogenesis and therapeutic approaches. Drugs 2004 64(4) 405-430. 

Hemox2 Iron recycling hemox2-/- mice (Dennery et al., 1998) Lung iron accumulation idiopathic pulmonary siderosis (Dearborn, 1997)... 

Raghu, G. et al., A placebo-controlled trial of interferon gamma-lb in patients with idiopathic pulmonary fibrosis, N. Engl. J Med, 350, 125, 2004. 

It regulates mucus production, inflammation, fibrosis and tissue remodeling. IL-13 is a therapeutic target for a number of disease states including asthma, idiopathic pulmonary fibrosis, ulcerative colitis, cancer and others. Its signaling is mediated via IL-4 type 2 receptor. The receptor consists of IL-4Ra and IL-13Ral and IL-13Ra2 chains. 

Cutaneous alternariosis (infection with Alternaria alter-nata) has been described in a 78-year-old farmer with idiopathic pulmonary fibrosis taking oral prednisone 20 mg/day (341). 

Ioannidou DJ, Stefanidou MP, Maraki SG, Panayiotides JG, Tosca AD. Cutaneous alternariosis in a patient with idiopathic pulmonary fibrosis. Int J Dermatol 2000 39(4) 293-5. 

Mariotta S, Pallone G, Li Bianchi E, Gilardi G, Bisetti A. Strongyloides stercoralis hyperinfection in a case of idiopathic pulmonary fibrosis. Panminerva Med 1996 38(l) 45-7. 

Ivy DD, Doran A, Clausen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004 93 943-6. 

A patient developed pulmonary fibrosis after having taken danazol for 2 months for idiopathic thrombocytopenic purpura (6). He developed bilateral pneumothoraces and pneumomediastinum and died. An association between danazol and lung fibrosis has been reported only once before here it could have been coincidental or a reflection of a pathological process underlying the originally diagnosed disorder. 

Pakhale S, Moltyaner Y, Chamberlain D, Lazar N. Rapidly progressive pulmonary fibrosis in a patient treated with danazol for idiopathic thrombocytopenic purpura. Can Resp J 2004 11 55-7. 

There is other evidence that transdermal estrogen replacement therapy has relatively little effect on hemostasis. In a case control study, 155 consecutive patients with a first documented episode of idiopathic venous thromboembolism, 92 of whom had had a pulmonary embolism and 63 a deep venous thrombosis, were compared with 381 healthy matched controls (88). Overall, 32 (21%) of the cases and 27 (7%) of the controls were current users of oral estrogen replacement therapy, whereas 30 (19%) cases and 93 (24%) controls were current users of transdermal estrogen replacement therapy. After adjustment for potential confounding variables, the odds ratios for venous thromboembolism in current users of oral and transdermal estrogen replacement therapy compared with non-users were 3.5 (95% Cl = 1.8, 6.8) and 0.9 (0.5, 1.6) respectively. Estimated risk for venous thromboembolism in current users of oral estrogen replacement therapy compared with transdermal users was 4.0 (1.9, 8.3). 

---